Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment
Mabwell上海生物科學部門在中國獲准使用Denosumab作爲骨腫瘤治療藥物
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊